New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 7, 2013
06:31 EDTALXNAlexion recommends rejection of mini-tender offer by TRC Capital
Alexion has been notified of an unsolicited "mini-tender" offer by TRC Capital Corporation to purchase up to 1.5M shares, or approximately 0.77%, of the outstanding Alexion common stock at a price of $90.50 per share. TRC's offer price represents approximately a 5.06% discount to the closing price of Alexion common stock on February 5. Alexion does not endorse TRC's offer and recommends that shareholders reject the offer and do not tender their shares. Alexion urges shareholders considering TRC's offer to obtain current market quotations for their shares, review the conditions to the offer, consult with their broker or financial adviser and exercise caution with respect to TRC's offer. Alexion is not associated in any way with TRC, its mini-tender offer or the offer documentation.
News For ALXN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 20, 2014
07:09 EDTALXNAlexion management to meet with Deutsche Bank
Subscribe for More Information
November 19, 2014
10:28 EDTALXNAlexion management to meet with Deutsche Bank
Subscribe for More Information
November 18, 2014
07:52 EDTALXNFDA Drug Safety & Risk Management Advisory Committee to hold a meeting
The Committee discusses the risk management of Alexion Pharmaceuticals' Eculizumab (Soliris) is a meeting being held at FDA Silver Spring, Maryland offices on November 18 at 9 am. Webcast Link
November 16, 2014
13:04 EDTALXNAlexion says data supports effectiveness of sustained Soliris treatment in aHUS
Subscribe for More Information
November 10, 2014
15:54 EDTALXNAmerican Society of Nephrology to hold a conference
Subscribe for More Information
09:20 EDTALXNJPMorgan biotech analyst to hold an analyst/industry conference call
U.S. SMid Biotech Analyst Rama, along with Key Opinion Leader Dr. Hickman Simmons from Vanderbilt University, discuss Alexion Pharmaceuticals' Asfotase Alfa and Hypophosophatasia on an Analyst/Industry conference call to be held on November 11 at 11 am.
06:31 EDTALXNAlexion announces planned retirement of co-founder, COO Stephen Squinto
Alexion announced the planned retirement of company co-founder Stephen Squinto, effective January 1, 2015. Squinto currently serves as Executive Vice President, Chief Global Operations Officer. He co-founded Alexion in 1992 with Leonard Bell, M.D., the Company’s principal founder and current Chairman and Chief Executive Officer.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use